Latest Ataxia Stories
WALTHAM, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the second quarter of fiscal year 2010, ended September 30, 2009.
Fragile X tremor/ataxia syndrome (FXTAS) is a recently recognized condition, which is actually one of the most prevalent heritable neurodegenerative diseases.
Discovery takes researchers 1 step closer to human clinical trials and could improve understanding of other diseases.
WALTHAM, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) reported today publication of research that identifies histone deacetylase 3 (HDAC 3) as an important enzyme target for therapeutic intervention in Friedreich's ataxia.
WALNUT CREEK, Calif., July 22 /PRNewswire/ -- Fragile X Syndrome (FXS) research is moving closer to finding a cure with the recent approval by The National Institutes of Health (NIH) of a comprehensive plan created by a group of leading scientists, parents and advocates.
ST. PETERSBURG, Fla., Dec. 22 /PRNewswire/ -- On December 17th, the new Bonefish Grill restaurant located at 5062 4th Street North in St.
LIESTAL, SWITZERLAND--(Marketwire - Oct. 10, 2008) - Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company with a focus on neuromuscular diseases, announced today the launch of CATENA(R) (idebenone) in Canada.
NEW HAVEN, Conn., Sept. 29, 2008 (GLOBE NEWSWIRE) -- People who suffer from health disorders are often treated as outcasts by society, often feared and even discriminated against. As such, the need to educate the public and help them understand the plight of sufferers simply cannot be ignored.
Santhera Pharmaceuticals has announced that Health Canada has approved SNT-MC17/idebenone, subject to certain conditions, for the treatment of Friedreich's Ataxia. Health Canada's decision is said to be the first marketing authorization worldwide for any Friedreich's Ataxia therapy.
Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announced today that Health Canada has approved with conditions SNT-MC17/idebenone for the treatment of Friedreich's Ataxia.
- The governor of a province or people.